This is abbreviated version for full version click on link
Drug Data Shouldn’t Be Secret
By PETER DOSHI and TOM JEFFERSON
Published: April 10, 2012
IN the fall of 2009, at the height of fears over swine
flu, our research group discovered that a majority of clinical trial
data for the anti-influenza drug Tamiflu
— data that proved, according to its manufacturer, that the drug reduced the
risk of hospitalization, serious complications and transmission — were missing,
unpublished and inaccessible to the research community. From what we could tell
from the limited clinical data that had been published in medical journals, the
country’s most widely used and heavily stockpiled influenza drug appeared no
more effective than aspirin
After we published this finding in the British Medical Journal at
the end of that year, Tamiflu’s manufacturer, Roche, announced that it would
release internal reports to back up its claims that the drug was effective in
reducing the complications of influenza. Roche promised access to data from 10
clinical trials, 8 of which had not been published a decade after completion,
representing more than 4,000 patients from every continent except Antarctica . Independent verification of the data seemed
imminent. But more than two years later, and despite repeated requests, we have
yet to receive even a single full trial report.
Some may argue that,
because the Food and Drug Administration approves drugs
for the United States
market based on these data, this is not a major cause for concern. But the
actual use of drugs is often driven by assumptions about drug safety and
effectiveness put forth by articles in peer-reviewed journals (sometimes
written by doctors affiliated with the drug manufacturers) and clinical
practice guidelines that can be entirely inconsistent with the F.D.A.’s
assessments.
In the case of
Tamiflu, some of these assumed properties led to stockpiling at great taxpayer expense — more
than $1.5 billion. The F.D.A. approved Tamiflu for the treatment of influenza
(on the basis that it could reduce the duration of flu symptoms by about a day); not for the
prevention of transmission.
The only agency in the
United States
that seems to have independently reviewed the original trial data never made
these claims. The F.D.A.’s conclusion — which it required Roche to print on
Tamiflu’s product labeling — is that “Tamiflu has not been shown to prevent”
complications like serious bacterial infections (for instance, pneumonia). It
seems that federal agencies like the C.D.C. and H.H.S., instead of conducting
an independent evaluation of Tamiflu, advocated stockpiling by referencing
claims in journal publications written by the drug’s manufacturer, ignoring the
F.D.A.’s assessment that those very claims were unproven.
……….but we found no decrease in risk of
hospitalization and no evidence that it could stop the spread of the virus.
More worrisome, we found suggestive evidence that Tamiflu interfered with the
body’s ability to produce antibodies against influenza — which could
affect the body’s response to influenza vaccine and its ability to fight off
future influenza infections. But to do a complete analysis, including
evaluating Tamiflu’s potential harms, we need the remainder of the data — the
full “clinical study report” — promised by Roche, but never delivered.
….In response to our
conclusions, which we published in January, the C.D.C.
defended its stance by once again pointing to Roche’s analyses. This is not the
way medical science should progress. Data secrecy is a disservice to those who
volunteer their bodies for clinical trials, and is dangerous to those being
asked to swallow approved medicines. Governments need to become better stewards
of the scientific process.
…………..We should not
have to wait for patients to be hurt by the medications they take, as recently
happened with the diabetes drug Avandia, before reviewing
this wealth of data.
Peter Doshi is a
postdoctoral fellow in comparative effectiveness research at Johns Hopkins
University School
of Medicine. Tom Jefferson is an independent epidemiologist with the Cochrane
Collaboration, an international nonprofit research organization.
http://www.nytimes.com/2012/04/11/opinion/drug-data-shouldnt-be-secret.html?_r=1
No comments:
Post a Comment